UBS Group
MSLE

UBS Group’s Satellos Bioscience MSLE Stock Holding History

UBS Group’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07K Buy
781
+753
+2,689% +$5.17K ﹤0.01% 8866
2026
Q1 		$158 Buy
+28
New +$275 ﹤0.01% 10065

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

UBS Group's MSLE Position: Q2 2026 in Review

UBS Group increased its Satellos Bioscience (MSLE) stake by 2,689% in Q2 2026, buying an estimated $5.17K and bringing the position to 781 shares worth $6.07K. The position accounts for ﹤0.01% of the portfolio, ranked #8866.

UBS Group first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • UBS Group held 781 shares of Satellos Bioscience worth $6.07K as of Q2 2026.
  • UBS Group bought 753 Satellos Bioscience shares in Q2 2026, an estimated $5.17K.
  • Satellos Bioscience made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8866 holding.
  • UBS Group first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.